Enzon Pharmaceuticals, Inc. (ENZN) Widens Q3 Loss on Lighter Sales
Tweet
Share
E-mailGet Alerts ENZN Hot Sheet
Price: $4.35 --0%
Financial Fact:
Net (loss) income: -4.61M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Net (loss) income: -4.61M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) reported Q3 EPS of ($0.19), versus ($0.14) reported last year. Revenue for the quarter came in at $10.44 million, versus $13.23 million reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- INVO Fertility (IVF) Tops Q2 EPS by 105c
- Femasys Inc. (FEMY) Misses Q2 EPS by 20c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
